Deposition and metabolism of inhaled ciclesonide in the human lung

European Respiratory Journal

Volumn 36, Issue 5, 2010, Pages 1113-1119

  Nave, R ^a   Watz, H ^b   Hoffmann, H ^c   Boss, H ^a   Magnussen, H ^b  

^a Nycomed GmbH   (Germany)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Ciclesonide; Human; In vivo; Lung metabolism

Indexed keywords

CICLESONIDE; DESISOBUTYRL CICLESONIDE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TISSUE LEVEL; ENTERITIS; FEMALE; FORCED EXPIRATORY VOLUME; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG LESION; MALE; PLEURA EMPYEMA; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATORY DISTRESS SYNDROME; SEPSIS; SINGLE DRUG DOSE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PILOT PROJECTS; PREGNENEDIONES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 78349301283     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00172309     Document Type: Article

References (29)

1. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368: 780-793.
2. Canonica GW. Treating asthma as an inflammatory disease. Chest 2006; 130: Suppl. 1, 21S-28S.
3. National Asthma Education and Prevention Program, Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics - 2002. J Allergy Clin Immunol 2002; 110: Suppl. 5, S141-S219.
4. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. www.ginasthma.org/Guidelineitem.asp??l152&l251&intId51561 Date last accessed: 2008. Date last updated: January 12, 2010.
5. Dietzel K, Engelstätter R, Keller A. Ciclesonide: an on-site activated steroid. Prog Respir Res 2001; 31: 91-93.
6. Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 2007; 73: 1657-1664.
7. Nave R, McCracken N. Metabolism of ciclesonide in the upper and lower airways. Reviewof available data. J Asthma Allergy 2008; 1: 11-18.
8. Belvisi MG, Bundschuh DS, Stoeck M, et al. . Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. J Pharmacol Exp Ther 2005; 314: 568-574.
9. Leach CL, Bethke TD, Boudreau RJ, et al. Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med 2006; 19: 117-126.
10. Newman S, Salmon A, Nave R, et al. High lung deposition of (99m)Tc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100: 375-384.
11. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005; 61: 203-208.
12. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005; 45: 146-152.
13. Nave R, Meyer W, Fuhst R, et al. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther 2005; 18: 390-396. (Pubitemid 41354264)
14. Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm Drug Dispos 2006; 27: 197-207.
15. Nave R, Fisher R, McCracken N. In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices. Respiratory Research 2007; 8: 65.
16. Nave R, Gunawardena KA, Zech K, et al. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar. Int J Clin Pharmacol Ther 2006; 44: 1-7. (Pubitemid 43085491)
17. Nave R, Drollmann A, Steinijans VW, et al. Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin. Int J Clin Pharmacol Ther 2005; 43: 264-270. (Pubitemid 40872613)
18. Drollmann A, Nave R, Steinijans VW, et al. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation. Clin Pharmacokinet 2006; 45: 729-736. (Pubitemid 43990573)
19. Mascher HJ, Zech K, Mascher DG. Sensitive simultaneous determination of ciclesonide, ciclesonide-M1-metabolite and fluticasone propionate in human serum by HPLC-MS/MS with APPI. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 869: 84-92.
20. Derom E, van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005; 18: 328-336. (Pubitemid 40804531)
21. Szefler S, Rohatagi S, Williams J, et al. Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005; 128: 1104-1114. (Pubitemid 41324383)
22. Nave R. Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide. Clin Pharmacokinet 2009; 48: 243-252.
23. Derom E, Louis R, Tiesler C, et al. Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma. Eur Respir J 2009; 33: 1277-1286.
24. Xu J, Nave R, Lahu G, et al. Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. J Clin Pharmacol 2010; [Epub ahead of print DOI: 10.1177/0091270009354994].
25. Cohen J, Douma WR, ten Hacken NHT, et al. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 2008; 31: 1213-1220.
26. Esmailpour N, Hogger P, Rabe KF, et al. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997; 10: 1496-1499. (Pubitemid 27311061)
27. Holz O, Zuhlke I, Einhaus M, et al. Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols. Pulm Pharmacol Ther 2004; 17: 233-238. (Pubitemid 38802982)
28. Van den Bosch JM, Westermann CJ, Aumann J, et al. Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharm Drug Dispos 1993; 14: 455-459. (Pubitemid 23186347)
29. Van den Brimk KIM, Boorsma M, Staal-van den Brekel AJ, et al. Evidence of the in vivo esterification of budesonide in human airways. Br J Pharmacol 2008; 66: 27-35. (Pubitemid 351836039)